A small biotech may give up on its ultra-rare disease drug over frustration with FDA; Here are the best biopharma CEOs of 2023

Taking stock of the drug industry, from the lab to the medicine chest

December 18, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Caitlin O'Hara for STAT STAT+ | 'We've exhausted all avenues': A small biotech may give up on its ultra-rare disease drug over frustration with FDA Stealth BioTherapeutics, which is developing a therapy for Barth syndrome, has had an especially trying time seeking FDA approval. By Ed Silverman STAT+ | Here are the best biopharma CEOs of 2023 Nods to the CEOs behind some of this year's biggest biopharma deals and most exciting new drug treatments. By Adam Feuerstein STAT+ | Wegovy may have another helpful trick: fighting inflammation via the brain, study finds A study in mice finds GLP-1 weight loss drugs act in the brain to reduce inflammation, which may help explain why they benefit heart health. By Elaine Chen Adobe STAT+ | Structure Therapeutics GLP-1 pill cuts blood sugar, weight in early diabetes study Blockbuster GLP-1 drugs like Wegovy and Mounjaro are injected. Pills would make the medicines more accessible and attractive to patients. By Adam Feuerstein

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser